Guj. Terce Labs.

{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "46.70",
    "chg": 0.77,
    "chgp": "1.68%",
    "dir": 1,
    "prev_price": "45.93",
    "mcapval": "35.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE499G01013",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "213 ",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gujarat Terce Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-3791473",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GujaratTerceLab_mojoScore_3791473.png",
        "date": "2026-01-14 08:12:14",
        "description": "Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators from mildly bearish to sideways, signalling a potential stabilisation in price action. However, the company’s fundamental challenges, including weak long-term growth and expensive valuation metrics, continue to weigh on investor sentiment."
      },
      {
        "title": "Gujarat Terce Laboratories Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-ltd-is-rated-strong-sell-3770883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3770883.png",
        "date": "2025-12-26 15:13:38",
        "description": "Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 December 2025, providing investors with the latest insights into the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3764311",
        "imagepath": "",
        "date": "2025-12-20 02:24:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Momentum and Outperformance</strong></p>\n<p>The stock has demonstrated strong momentum over the past week and month, delivering returns of 7.98% and 11.64% respectively, significantly outperforming the Sensex which declined marginally in the same periods. This recent surge is further underscored by the stock’s consecutive gains over the last two days, accumulating a 12.21% return in that timeframe. On 19-Dec, the stock reached an intraday high of ₹48.50, marking a 6.62% increase from its low of ₹43.90, indicating robust intraday volatility and investor interest.</p>\n<p>Despite this positive short-term trend, the weighted average price suggests that a greater volume of shares traded closer to the day’s low, hinting at some selling pressure or cautious profit-taking even amid ..."
      },
      {
        "title": "Gujarat Terce Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3754854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3754854.png",
        "date": "2025-12-10 08:16:27",
        "description": "Gujarat Terce Laboratories has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. Despite recent positive quarterly financial results, the company’s longer-term fundamentals and technical outlook present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gujarat-terce-laboratories-downgraded-to-sell-amid-mixed-technicals-and-weak-fundamentals-3747788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GujaratTerceLab_mojoScore_3747788.png",
        "date": "2025-12-05 08:09:35",
        "description": "Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3747111",
        "imagepath": "",
        "date": "2025-12-04 22:49:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.</p>\n<p>Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ..."
      },
      {
        "title": "Is Guj. Terce Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-guj-terce-labs-overvalued-or-undervalued-3709851",
        "imagepath": "",
        "date": "2025-11-18 08:22:54",
        "description": "As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.\n\nIn comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra..."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3683702",
        "imagepath": "",
        "date": "2025-11-09 22:47:36",
        "description": "Answer:\nThe historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.\n\nBreakdown:\nGuj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ..."
      },
      {
        "title": "Are Guj. Terce Labs. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-terce-labs-latest-results-good-or-bad-3683316",
        "imagepath": "",
        "date": "2025-11-09 19:14:31",
        "description": "Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress.\n\nNet profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress.\n\nDespite the company mainta..."
      }
    ],
    "total": 171,
    "sid": "890385",
    "stock_news_url": "https://www.marketsmojo.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Please find enclosed herewith the certificate received from Bigshare Services Private Limited in respect of dematerialisation request received by them for the Company during the period 1 October 2025 to 31 December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for The Unaudited Financial Results For The Third Quarter And Nine Months Ending On 31-12-2025.",
      "datetime": "28-Dec-2025",
      "details": "Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve Unaudited Financial results for the third quarter and nine months ending on 31-12-2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "28-Dec-2025",
      "details": "Closure of Trading window: Unaudited Financial Results for the quarter ended on 31st March 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "04 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Gujarat Terce Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-01-14 08:12:14

Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators from mildly bearish to sideways, signalling a potential stabilisation in price action. However, the company’s fundamental challenges, including weak long-term growth and expensive valuation metrics, continue to weigh on investor sentiment.

Read full news article

Gujarat Terce Laboratories Ltd is Rated Strong Sell

2025-12-26 15:13:38

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 December 2025, providing investors with the latest insights into the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Why is Guj. Terce Labs. falling/rising?

2025-12-20 02:24:32

Short-Term Price Momentum and Outperformance

The stock has demonstrated strong momentum over the past week and month, delivering returns of 7.98% and 11.64% respectively, significantly outperforming the Sensex which declined marginally in the same periods. This recent surge is further underscored by the stock’s consecutive gains over the last two days, accumulating a 12.21% return in that timeframe. On 19-Dec, the stock reached an intraday high of ₹48.50, marking a 6.62% increase from its low of ₹43.90, indicating robust intraday volatility and investor interest.

Despite this positive short-term trend, the weighted average price suggests that a greater volume of shares traded closer to the day’s low, hinting at some selling pressure or cautious profit-taking even amid ...

Read full news article

Gujarat Terce Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-10 08:16:27

Gujarat Terce Laboratories has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. Despite recent positive quarterly financial results, the company’s longer-term fundamentals and technical outlook present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-05 08:09:35

Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile.

Read full news article

How has been the historical performance of Guj. Terce Labs.?

2025-12-04 22:49:00

Revenue and Profitability Trends

Over the three fiscal years ending March 2021, Guj. Terce Labs. witnessed a notable decline in net sales, falling from ₹37.54 crores in March 2020 to ₹25.18 crores in March 2021. This represents a significant contraction of approximately 33%, reversing the growth seen in the previous year when sales had increased from ₹31.03 crores in March 2019 to ₹37.54 crores in March 2020. The absence of other operating income throughout these years indicates that the company’s revenue streams are solely dependent on its core operations.

Cost management has been a mixed bag. Raw material costs and purchase of finished goods decreased in line with lower sales, but employee costs remained relatively high, only marginally reduced from ₹15.13 crores in ...

Read full news article

Is Guj. Terce Labs. overvalued or undervalued?

2025-11-18 08:22:54

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms. In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra...

Read full news article

How has been the historical performance of Guj. Terce Labs.?

2025-11-09 22:47:36

Answer: The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year. Breakdown: Guj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ...

Read full news article

Are Guj. Terce Labs. latest results good or bad?

2025-11-09 19:14:31

Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress. Net profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress. Despite the company mainta...

Read full news article

View All News